# Rahul Dhanda

> Rahul Dhanda is the Boston-based co-founder, president and CEO of Syntis Bio. A Wesleyan history graduate and MIT Sloan MBA, he previously co-founded Sherlock Biosciences and spent roughly a decade at T2 Biosystems. His career also includes authorship of Guiding Icarus, co-founding BLASTID and board service at Constructive Bio.

- **Role:** Co-founder, President and CEO at Syntis Bio
- **Organizations:** Syntis Bio, BLASTID, Constructive Bio, Sherlock Biosciences (former), T2 Biosystems (former), Boston Scientific (former), Interleukin Genetics (former), The 221b Foundation (founding board member)
- **Education:** BA in History, Wesleyan University, MBA, MIT Sloan School of Management
- **Known for:** Authored Guiding Icarus, published by Wiley in 2002., Led corporate partnering activity bringing more than $40 million to T2 Biosystems., Led a Boston Scientific team responsible for more than $100 million in annual revenue.

## Career timeline

- **1995** — Graduated from Wesleyan University.
- **2001-2004** — Worked in business development at Interleukin Genetics, May 2001 to June 2004.
- **2002** — Published Guiding Icarus: Merging Bioethics with Corporate Interests.
- **2005** — Joined Boston Scientific in marketing in June.
- **2008** — Joined T2 Biosystems.
- **2010** — Became vice president of marketing at T2.
- **2016** — Became senior vice president of corporate development at T2 in February.
- **2018-2019** — Co-founded Sherlock Biosciences; its founders came together in 2018 and it publicly launched in 2019.
- **2020** — Named to Boston Business Journal Power50; founding board member of the 221b Foundation.
- **2022** — Co-founded Syntis Bio with Robert Langer and Giovanni Traverso.
- **2023** — Joined Constructive Bio as a non-executive director in November.
- **2024** — Syntis publicly launched in June.
- **2025** — Syntis announced a $33 million Series A in July.

## Achievements

- Authored Guiding Icarus, published by Wiley in 2002.
- Led corporate partnering activity bringing more than $40 million to T2 Biosystems.
- Led a Boston Scientific team responsible for more than $100 million in annual revenue.
- Named to Boston Business Journal Power50 in 2020.
- Co-founded Syntis Bio, Sherlock Biosciences and BLASTID.
- Helped establish the 221b Foundation to support racial and gender diversity in STEM.

## Latest updates

- **2026-06** — Welcomed Matt Dallas as Syntis Bio CFO, emphasizing financial and business infrastructure for growth.
- **2025-07** — Syntis announced a $33 million Series A led by Cerberus Ventures; Dhanda credited current and former team members.

## Links

- LinkedIn: https://www.linkedin.com/in/dhanda

---

Profile page: https://yespress.io/rahul-dhanda
Published by YesPress — https://yespress.io
Last updated: 2026-10-26